ArticleJournal of Korean medical science2026
A Nationwide Study on Pretransfusion Testing for 10 Years in Korea Using Health Insurance Review and Assessment Claims Data.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssessing pretransfusion testing utilization at medical institutions on a nationwide scale can be challenging. This study aimed to evaluate the status of pretransfusion testing in Korea by analyzing insurance claims data.
methodsWe identified all claims including pretransfusion testing or blood transfusion made between January 2011 and December 2020 from the Korean Health Insurance Review and Assessment Service database. ABO/RhD typing, antibody screening and identification, and crossmatching were analyzed according to the hospital type.
resultsA total of 42,968,177 claims from 20,088,744 patients were analyzed. The median ratios of ABO serum typing to cell typing were 1.000 for tertiary hospitals, 0.998 for secondary hospitals, 0.000 for primary hospitals, and 0.000 for clinics (
conclusionThe application of pretransfusion testing considerably differs according to the type of hospital in Korea. Primary hospitals and clinics need education and improvement in practice to pursue safe blood transfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.